Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013
Volume 53, Issue -, Pages 37-58Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-011112-140244
Keywords
epoxy-fatty acid; hypertension; inflammation; pain; cancer
Categories
Funding
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002710, R37ES002710, P42ES004699] Funding Source: NIH RePORTER
- NIEHS NIH HHS [R01 ES002710, P42 ES004699, P42 ES04699, R37 ES002710, ES02710] Funding Source: Medline
Ask authors/readers for more resources
The presence of epoxyeicosatrienoic acids (EETs) in tissues and their metabolism by soluble epoxide hydrolase (sEH) to 1,2-diols were first reported 30 years ago. However, appreciation of their importance in cell biology and physiology has greatly accelerated over the past decade with the discovery of metabolically stable inhibitors of sEH, the commercial availability of EETs, and the development of analytical methods for the quantification of EETs and their diols. Numerous roles of EETs in regulatory biology now are clear, and the value of sEH inhibition in various animal models of disease has been demonstrated. Here, we review these results and discuss how the pharmacological stabilization of EETs and other natural epoxy-fatty acids could lead to possible disease therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available